Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives

Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies ag...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics and personalized medicine 2016-01, Vol.9 (Issue 1), p.7-16
Main Author: Myers, Meagan B
Format: Article
Language:English
Subjects:
Biomarkers
Biopsy
Breast cancer
Cancer
Cancer therapies
Care and treatment
Clinical trials
Development and progression
Diagnostic reagents
Dissection
Endocrine therapy
Epidermal growth factor
estrogen receptor
FDA approval
Feasibility studies
Food
Gene expression
Health aspects
HER2
in vitro diagnostics
Lymphatic system
Marketing
Mastectomy
Medical prognosis
Medicine
multigene assay
Oncology, Experimental
Patients
Precision medicine
Review
Surgery
Tumors
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c573t-719e0565b99a46ce0961a598393a1341b99b99a4c314a0f5b008fd00f0f02a773
cites
container_end_page 16
container_issue Issue 1
container_start_page 7
container_title Pharmacogenomics and personalized medicine
container_volume 9
creator Myers, Meagan B
description Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.
doi_str_mv 10.2147/PGPM.S56055
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_937a6f4f114043f39288924887f60c09</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A503297605</galeid><doaj_id>oai_doaj_org_article_937a6f4f114043f39288924887f60c09</doaj_id><sourcerecordid>A503297605</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-719e0565b99a46ce0961a598393a1341b99b99a4c314a0f5b008fd00f0f02a773</originalsourceid><addsrcrecordid>eNptktFrFDEQxhdRbK0--S4LgghyZ7LZTTY-CKVoLVQsWJ_DXHayl2M32SbZiv-9uV6tdyJ5yDDzmy_M5CuKl5QsK1qL91fnV1-X3xtOmuZRcUypaBeCcP54Lz4qnsW4ITlqWfW0OKp427QNI8eFuYbQY8KuTGsMMFmM5U-b1qX24wTOeld2FnrnY7I6ltZtuXIEBz2O6FLpTbkKCDGVGpzG8KHUcwjbyoQhTqiTvcX4vHhiYIj44v4-KX58_nR99mVx-e384uz0cqEbwdJCUImk4c1KSqi5RiI5hUa2TDKgrKY5f1fSjNZATLMipDUdISafCoRgJ8XFTrfzsFFTsCOEX8qDVXcJH3oFIU8yoJJMADe1obQmNTNMVm0rq7ptheFEE5m1Pu60pnk1YqfzTAGGA9HDirNr1ftbVQtGpGRZ4O29QPA3M8akRhs1DgM49HNUVPA6D0Upz-jrf9CNn4PLq1JVVclacFrRv1QPeQDrjM_v6q2oOm0Iq6TIJsjU8j9UPh2OVnuHxub8QcObvYY1wpDW0Q9zyr8fD8F3O1AHH2NA87AMStTWi2rrRbXzYqZf7e_vgf1jPvYbqkfW5Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229476121</pqid></control><display><type>article</type><title>Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives</title><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Myers, Meagan B</creator><creatorcontrib>Myers, Meagan B</creatorcontrib><description>Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.</description><identifier>ISSN: 1178-7066</identifier><identifier>EISSN: 1178-7066</identifier><identifier>DOI: 10.2147/PGPM.S56055</identifier><identifier>PMID: 26858530</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Biomarkers ; Biopsy ; Breast cancer ; Cancer ; Cancer therapies ; Care and treatment ; Clinical trials ; Development and progression ; Diagnostic reagents ; Dissection ; Endocrine therapy ; Epidermal growth factor ; estrogen receptor ; FDA approval ; Feasibility studies ; Food ; Gene expression ; Health aspects ; HER2 ; in vitro diagnostics ; Lymphatic system ; Marketing ; Mastectomy ; Medical prognosis ; Medicine ; multigene assay ; Oncology, Experimental ; Patients ; Precision medicine ; Review ; Surgery ; Tumors ; Womens health</subject><ispartof>Pharmacogenomics and personalized medicine, 2016-01, Vol.9 (Issue 1), p.7-16</ispartof><rights>COPYRIGHT 2016 Dove Medical Press Limited</rights><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Myers. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-719e0565b99a46ce0961a598393a1341b99b99a4c314a0f5b008fd00f0f02a773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2229476121/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2229476121?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26858530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Myers, Meagan B</creatorcontrib><title>Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives</title><title>Pharmacogenomics and personalized medicine</title><addtitle>Pharmgenomics Pers Med</addtitle><description>Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.</description><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Diagnostic reagents</subject><subject>Dissection</subject><subject>Endocrine therapy</subject><subject>Epidermal growth factor</subject><subject>estrogen receptor</subject><subject>FDA approval</subject><subject>Feasibility studies</subject><subject>Food</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>HER2</subject><subject>in vitro diagnostics</subject><subject>Lymphatic system</subject><subject>Marketing</subject><subject>Mastectomy</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>multigene assay</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Review</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Womens health</subject><issn>1178-7066</issn><issn>1178-7066</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptktFrFDEQxhdRbK0--S4LgghyZ7LZTTY-CKVoLVQsWJ_DXHayl2M32SbZiv-9uV6tdyJ5yDDzmy_M5CuKl5QsK1qL91fnV1-X3xtOmuZRcUypaBeCcP54Lz4qnsW4ITlqWfW0OKp427QNI8eFuYbQY8KuTGsMMFmM5U-b1qX24wTOeld2FnrnY7I6ltZtuXIEBz2O6FLpTbkKCDGVGpzG8KHUcwjbyoQhTqiTvcX4vHhiYIj44v4-KX58_nR99mVx-e384uz0cqEbwdJCUImk4c1KSqi5RiI5hUa2TDKgrKY5f1fSjNZATLMipDUdISafCoRgJ8XFTrfzsFFTsCOEX8qDVXcJH3oFIU8yoJJMADe1obQmNTNMVm0rq7ptheFEE5m1Pu60pnk1YqfzTAGGA9HDirNr1ftbVQtGpGRZ4O29QPA3M8akRhs1DgM49HNUVPA6D0Upz-jrf9CNn4PLq1JVVclacFrRv1QPeQDrjM_v6q2oOm0Iq6TIJsjU8j9UPh2OVnuHxub8QcObvYY1wpDW0Q9zyr8fD8F3O1AHH2NA87AMStTWi2rrRbXzYqZf7e_vgf1jPvYbqkfW5Q</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Myers, Meagan B</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives</title><author>Myers, Meagan B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-719e0565b99a46ce0961a598393a1341b99b99a4c314a0f5b008fd00f0f02a773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Diagnostic reagents</topic><topic>Dissection</topic><topic>Endocrine therapy</topic><topic>Epidermal growth factor</topic><topic>estrogen receptor</topic><topic>FDA approval</topic><topic>Feasibility studies</topic><topic>Food</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>HER2</topic><topic>in vitro diagnostics</topic><topic>Lymphatic system</topic><topic>Marketing</topic><topic>Mastectomy</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>multigene assay</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Review</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Myers, Meagan B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmacogenomics and personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Myers, Meagan B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives</atitle><jtitle>Pharmacogenomics and personalized medicine</jtitle><addtitle>Pharmgenomics Pers Med</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><issue>Issue 1</issue><spage>7</spage><epage>16</epage><pages>7-16</pages><issn>1178-7066</issn><eissn>1178-7066</eissn><abstract>Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>26858530</pmid><doi>10.2147/PGPM.S56055</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-7066
ispartof Pharmacogenomics and personalized medicine, 2016-01, Vol.9 (Issue 1), p.7-16
issn 1178-7066
1178-7066
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_937a6f4f114043f39288924887f60c09
source Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central
subjects Biomarkers
Biopsy
Breast cancer
Cancer
Cancer therapies
Care and treatment
Clinical trials
Development and progression
Diagnostic reagents
Dissection
Endocrine therapy
Epidermal growth factor
estrogen receptor
FDA approval
Feasibility studies
Food
Gene expression
Health aspects
HER2
in vitro diagnostics
Lymphatic system
Marketing
Mastectomy
Medical prognosis
Medicine
multigene assay
Oncology, Experimental
Patients
Precision medicine
Review
Surgery
Tumors
Womens health
title Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A27%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20therapies%20with%20companion%20diagnostics%20in%20the%20management%20of%20breast%20cancer:%20current%20perspectives&rft.jtitle=Pharmacogenomics%20and%20personalized%20medicine&rft.au=Myers,%20Meagan%20B&rft.date=2016-01-01&rft.volume=9&rft.issue=Issue%201&rft.spage=7&rft.epage=16&rft.pages=7-16&rft.issn=1178-7066&rft.eissn=1178-7066&rft_id=info:doi/10.2147/PGPM.S56055&rft_dat=%3Cgale_doaj_%3EA503297605%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c573t-719e0565b99a46ce0961a598393a1341b99b99a4c314a0f5b008fd00f0f02a773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2229476121&rft_id=info:pmid/26858530&rft_galeid=A503297605&rfr_iscdi=true